As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
RxSight reported Q2 total revenue of $33.7 million, boosted by $6.5 million from the Alcon collaboration, while core product sales declined 19% year-over-year to $27.2 million.
The company appointed Aziz Mottiwala as President and CEO and withdrew its 2026 financial outlook to conduct a comprehensive strategic review under the new leadership.
RxSight maintains a strong balance sheet with approximately $209 million in cash and short-term investments as of June 30, 2026.